Supposedly the top 5 based simply on the performance of the stocks YTD up to December 20th.  YTD we're up ~48.5% which should have had us in 3rd on this list.  But apparently Apabetalone not only shows promise in reducing MACE for Diabetic patients, it also makes the stock for Resverlogix invisible too.  

https://investingnews.com/daily/life-science-investing/biotech-investing/top-biotech-stocks-tsx/

Here's the chart comparison of the 5 stocks mentioned with RVX added: